Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

751
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
751
Metastasis02:30

Metastasis

5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.

BMC infectious diseases·2026
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Deployment of AI-driven automated quality control of whole-slide images in a large tertiary cancer center.

Journal of pathology informatics·2026
Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026

Related Experiment Video

Updated: Apr 29, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

20.2K

Recommended Terms and Definitions From the 2025 NCCN Biomarkers Resource Committee.

Melissa Y Tjota1, Jennelle C Hodge2, Lawrence J Jennings3

  • 11Department of Pathology, University of Chicago Medicine, Chicago, IL.

Journal of the National Comprehensive Cancer Network : JNCCN
|April 27, 2026
PubMed
Summary

The NCCN Biomarkers Resource Committee (BRC) standardized biomarker testing terminology to improve consistency in NCCN Guidelines. This initiative clarifies terms for genomic events and testing approaches for clinical providers.

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.6K
Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

5.1K

Related Experiment Videos

Last Updated: Apr 29, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

20.2K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.6K
Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
08:20

Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer

Published on: May 21, 2019

5.1K

Area of Science:

  • Oncology
  • Biomarker Science
  • Clinical Practice Guidelines

Background:

  • The NCCN Biomarkers Resource Committee (BRC) was formed to offer molecular expertise for biomarker testing in NCCN publications.
  • Inconsistencies in biomarker testing terminology were identified across NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).

Purpose of the Study:

  • To reduce inconsistencies and standardize biomarker testing terms and definitions within NCCN Guidelines.
  • To define commonly used terms for clinical care providers.
  • To provide recommendations for standardized biomarker terminology use in NCCN Guidelines and publications.

Main Methods:

  • Reviewed current professional society guidelines for terminology.
  • Assessed terminology utilization within existing NCCN Guidelines.
  • Explored common parlance and identified synonyms for biomarker testing terms.
  • Discussed and nominated preferred and nonpreferred terminology with rationales.

Main Results:

  • Identified key areas needing terminology clarification, including types of genomic events and testing approaches.
  • Established preferred terminology and definitions for biomarker testing.
  • Provided recommendations for consistent application of these terms.

Conclusions:

  • Standardized biomarker terminology is crucial for consistent interpretation and application of NCCN Guidelines.
  • The BRC's efforts aim to enhance clarity and reduce ambiguity in biomarker testing guidance.
  • Adoption of standardized terms will improve molecular expertise and guidance in oncology.